- SGLT2 Inhibitors Protect Cardiomyocytes From Myocardial Infarction: A Direct mechanism?
Jian Zhang et al, 2022, Future Cardiology CrossRef - Effect of Dapagliflozin on Patients with Rheumatic Heart Disease Mitral Stenosis
An Aldia Asrial et al, 2023, Journal of Clinical Medicine CrossRef - Coinfection of Dermal Fibroblasts by Human Cytomegalovirus and Human Herpesvirus 6 Can Boost the Expression of Fibrosis-Associated MicroRNAs
Irene Soffritti et al, 2023, Microorganisms CrossRef - Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition
Sha Chen et al, 2024, Biomedicine & Pharmacotherapy CrossRef - APOB and CCL17 as Mediators in the Protective Effect of SGLT2 Inhibition against Myocardial Infarction: Insights from Proteome-wide Mendelian Randomization
Lili Shi et al, 2024, European Journal of Pharmacology CrossRef - The interaction between non-coding RNAs and SGLT2: A review
Joanna Jarosz-Popek et al, 2024, International Journal of Cardiology CrossRef - Molecular mechanism of triptolide in myocardial fibrosis through the Wnt/β-catenin signaling pathway
Yiwen Zhang et al, 2024, Scandinavian Cardiovascular Journal CrossRef - Doxorubicin‑induced cardiomyopathy is mitigated by empagliflozin via the modulation of endoplasmic reticulum stress pathways
Akshi Malik et al, 2024, Molecular Medicine Reports CrossRef